4.7 Letter

Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis et al

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 81, Issue 12, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-218942

Keywords

biological therapy; familial Mediterranean fever; outcome assessment; health care

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available